SCHEMBL2069877

SCHEMBL2069877

CCCCC(O)c1[c]nccc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BDKRB2 P30411 2/20 0.36
ALDH1A1 P00352 3/20 0.35
KDM4E B2RXH2 1/20 0.35
CYP3A4 P08684 2/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
CA2 P00918 1/20 0.33
KMT2A Q03164 3/20 0.32
TSHR P16473 3/20 0.32
MAPK1 P28482 2/20 0.32
MEN1 O00255 2/20 0.32
LMNA P02545 2/20 0.32
TP53 P04637 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP2C9 P11712 1/20 0.32
NFKB1 P19838 1/20 0.32
CYP2C19 P33261 1/20 0.32
HIF1A Q16665 1/20 0.32
GMNN O75496 1/20 0.32
ALOX5 P09917 1/20 0.32
HPGD P15428 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2011912 0.95 MAPK1 (0.36) BDKRB2ALDH1A1CYP3A4L3MBTL1KMT2A
SCHEMBL3548162 0.91 TP53 (0.32) LMNATP53
SCHEMBL2067545 0.84 LMNA (0.41) LMNARECQL
SCHEMBL3585938 0.71 ALDH1A1 (0.40) ALDH1A1KDM4ECYP3A4CA2KMT2A
SCHEMBL8829972 0.71 NPC1 (0.30) L3MBTL1
SCHEMBL2818903 0.71 TSHR (0.35) ALDH1A1L3MBTL1KMT2ATSHRMEN1
SCHEMBL7770582 0.70
SCHEMBL18043744 0.69 SLC6A4 (0.32)
SCHEMBL2068129 0.69 TRPA1 (0.32)
SCHEMBL1494160 0.69 ALDH1A1 (0.43) ALDH1A1KDM4ECYP3A4L3MBTL1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140005163-A1 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES NOVARTIS AG (CH) 2014-01-02 US disclosed
US-8476294-B2 1H-imidazo[4,5-c]quinolinone derivatives NOVARTIS AG (CH) 2013-07-02 US disclosed
EP-2438064-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES Novartis AG (CH) 2012-04-11 EP disclosed
US-20100317657-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES NOVARTIS AG 2010-12-16 US disclosed
WO-2010139731-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES NOVARTIS AG (CH) 2010-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317657-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES PRKCA, CSNK1A1, ABL1 BDKRB2 911/4885ALDH1A1 2405/4885KDM4E 1280/4885
US-20140005163-A1 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES PRKCA, CSNK1A1, ABL1 BDKRB2 911/4885ALDH1A1 2405/4885KDM4E 1280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.